Overivew

Prostate Study NRG GU003

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

Objective

Post-prostatectomy RT has traditionally been delivered in conventional fractionation that can take as long as 6 to 8 weeks to deliver. The proposed study explores an alternative RT dose-fractionation schedule that exploits the radiobiological properties of prostate cancer to shorten overall treatment time called hypofractionation. Patients will be randomized (1:1) to either conventional radiation or hypofractionated radiation.

The potential advantages of hypofractionation are: 1) increased convenience to patients because of fewer treatment days, 2) reduced cost to patients because of reduced travel expenses and copays, 3) improved resource utilization for physicians because of the fewer number of treatments per patient and overall, 4) and consequently reduced cost to society.

In prostate cancer specifically, hypofractionation has the added potential advantage of not increasing toxicity (primary endpoint of Phase II) compared to standard fractionation, while delivering a higher biological dose and therefore increase efficacy (primary endpoint for Phase III).

Principal Investigator(s)

William Reece, MD, Radiation Oncology, Overlake Cancer Center

Contact

Stephanie Porenta, RN BSN CCRC: 425.467.3986, Stephanie.Porenta@overlakehospital.org

Tina Fortney, RN BSN CCRC: 425.688.5407, Tina.Fortney@overlakehospital.org

Clinical Trial Categories

Oncology

Additional Information

https://www.clinicaltrials.gov/ct2/show/NCT03274687?term=Prostate+NRG+GU003&rank=1

Location

Overlake Medical Center
1035 116th Ave. NE 
Bellevue, WA 98004
Main: 425.688.5000

Find locations + directions

Find locations + directions

Contact us

Contact us

View all classes + events

View all classes + events